Tumor Proliferative Rate and Response to Chemotherapy

  1. James O. Armitage, MD
  1. University of Nebraska Medical Center
    Omaha, NE 68198-3332

    Excerpt

    One of the widely held ideas in oncology is that rapidly dividing tumors are sensitive to chemotherapy, whereas slowly growing tumors are resistant. This idea might have been fostered by the early success of chemotherapy in Burkitt lymphoma—perhaps the most rapidly proliferating human tumor. Also, the common "solid tumors" generally proliferate slowly and respond poorly to chemotherapy. However, another explanation for the same observations is that factors other than tumor growth rate determine sensitivity to chemotherapy but that some rapidly dividing tumors happen to be sensitive to chemotherapy. If the latter were true and because rapidly proliferating tumors might become

    This 100-word excerpt has been provided in the absence of an abstract.

    Article and Author Information

    • Requests for Reprints: James O. Armitage, MD, Department of Internal Medicine, University of Nebraska Medical Center, 600 South 42nd Street, Omaha, NE 68198-3332.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement